S&P 500   3,376.81 (+0.41%)
DOW   27,870.96 (+0.32%)
QQQ   281.46 (+1.30%)
AAPL   116.92 (+0.96%)
MSFT   212.88 (+1.21%)
FB   266.76 (+1.86%)
GOOGL   1,489.07 (+1.60%)
AMZN   3,195.28 (+1.48%)
TSLA   436.96 (+1.85%)
NVDA   545.95 (+0.87%)
BABA   291.95 (-0.69%)
CGC   14.26 (-0.42%)
MU   47.79 (+1.77%)
GE   6.19 (-0.64%)
AMD   83.83 (+2.24%)
T   28.51 (+0.00%)
F   6.67 (+0.15%)
ACB   4.66 (+0.22%)
GILD   63.09 (-0.16%)
NFLX   509.60 (+1.91%)
DIS   124.58 (+0.40%)
BA   169.45 (+2.54%)
BAC   24.04 (-0.21%)
S&P 500   3,376.81 (+0.41%)
DOW   27,870.96 (+0.32%)
QQQ   281.46 (+1.30%)
AAPL   116.92 (+0.96%)
MSFT   212.88 (+1.21%)
FB   266.76 (+1.86%)
GOOGL   1,489.07 (+1.60%)
AMZN   3,195.28 (+1.48%)
TSLA   436.96 (+1.85%)
NVDA   545.95 (+0.87%)
BABA   291.95 (-0.69%)
CGC   14.26 (-0.42%)
MU   47.79 (+1.77%)
GE   6.19 (-0.64%)
AMD   83.83 (+2.24%)
T   28.51 (+0.00%)
F   6.67 (+0.15%)
ACB   4.66 (+0.22%)
GILD   63.09 (-0.16%)
NFLX   509.60 (+1.91%)
DIS   124.58 (+0.40%)
BA   169.45 (+2.54%)
BAC   24.04 (-0.21%)
S&P 500   3,376.81 (+0.41%)
DOW   27,870.96 (+0.32%)
QQQ   281.46 (+1.30%)
AAPL   116.92 (+0.96%)
MSFT   212.88 (+1.21%)
FB   266.76 (+1.86%)
GOOGL   1,489.07 (+1.60%)
AMZN   3,195.28 (+1.48%)
TSLA   436.96 (+1.85%)
NVDA   545.95 (+0.87%)
BABA   291.95 (-0.69%)
CGC   14.26 (-0.42%)
MU   47.79 (+1.77%)
GE   6.19 (-0.64%)
AMD   83.83 (+2.24%)
T   28.51 (+0.00%)
F   6.67 (+0.15%)
ACB   4.66 (+0.22%)
GILD   63.09 (-0.16%)
NFLX   509.60 (+1.91%)
DIS   124.58 (+0.40%)
BA   169.45 (+2.54%)
BAC   24.04 (-0.21%)
S&P 500   3,376.81 (+0.41%)
DOW   27,870.96 (+0.32%)
QQQ   281.46 (+1.30%)
AAPL   116.92 (+0.96%)
MSFT   212.88 (+1.21%)
FB   266.76 (+1.86%)
GOOGL   1,489.07 (+1.60%)
AMZN   3,195.28 (+1.48%)
TSLA   436.96 (+1.85%)
NVDA   545.95 (+0.87%)
BABA   291.95 (-0.69%)
CGC   14.26 (-0.42%)
MU   47.79 (+1.77%)
GE   6.19 (-0.64%)
AMD   83.83 (+2.24%)
T   28.51 (+0.00%)
F   6.67 (+0.15%)
ACB   4.66 (+0.22%)
GILD   63.09 (-0.16%)
NFLX   509.60 (+1.91%)
DIS   124.58 (+0.40%)
BA   169.45 (+2.54%)
BAC   24.04 (-0.21%)
Log in
NASDAQ:MESO

Mesoblast Stock Forecast, Price & News

$18.58
-0.61 (-3.18 %)
(As of 10/1/2020 03:45 AM ET)
Add
Compare
Today's Range
$18.06
Now: $18.58
$18.79
50-Day Range
$11.33
MA: $17.52
$19.81
52-Week Range
$3.12
Now: $18.58
$21.28
Volume883 shs
Average Volume827,633 shs
Market Capitalization$2.18 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.64
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Read More
Mesoblast logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.05 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MESO
Previous SymbolOTCMKTS:MBLTY
CUSIPN/A
CIKN/A
Phone61-3-9639-6036

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.16 million
Book Value$4.70 per share

Profitability

Net Income$-77,940,000.00
Net Margins-242.38%

Miscellaneous

Employees81
Market Cap$2.18 billion
Next Earnings Date11/23/2020 (Estimated)
OptionableOptionable
$18.58
-0.61 (-3.18 %)
(As of 10/1/2020 03:45 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MESO News and Ratings via Email

Sign-up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mesoblast (NASDAQ:MESO) Frequently Asked Questions

How has Mesoblast's stock been impacted by Coronavirus?

Mesoblast's stock was trading at $6.0250 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MESO stock has increased by 208.4% and is now trading at $18.58.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Mesoblast?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Mesoblast
.

When is Mesoblast's next earnings date?

Mesoblast is scheduled to release its next quarterly earnings announcement on Monday, November 23rd 2020.
View our earnings forecast for Mesoblast
.

How were Mesoblast's earnings last quarter?

Mesoblast limited (NASDAQ:MESO) issued its earnings results on Wednesday, August, 26th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.18. The firm earned $0.70 million during the quarter, compared to analyst estimates of $13.43 million. Mesoblast had a negative return on equity of 15.49% and a negative net margin of 242.38%.
View Mesoblast's earnings history
.

What price target have analysts set for MESO?

5 analysts have issued 12-month price targets for Mesoblast's shares. Their forecasts range from $14.00 to $23.00. On average, they expect Mesoblast's stock price to reach $19.05 in the next year. This suggests a possible upside of 2.5% from the stock's current price.
View analysts' price targets for Mesoblast
.

Are investors shorting Mesoblast?

Mesoblast saw a increase in short interest in September. As of September 15th, there was short interest totaling 2,660,000 shares, an increase of 21.5% from the August 31st total of 2,190,000 shares. Based on an average daily trading volume, of 1,050,000 shares, the days-to-cover ratio is currently 2.5 days.
View Mesoblast's Short Interest
.

Who are some of Mesoblast's key competitors?

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), Novavax (NVAX), Crispr Therapeutics (CRSP), Micron Technology (MU), AbbVie (ABBV) and Alibaba Group (BABA).

Who are Mesoblast's key executives?

Mesoblast's management team includes the following people:
  • Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 62)
  • Dr. Donna L. Skerrett, Chief Medical Officer (Age 62)
  • Mr. Roger D. Brown BA, Head of Spinal Orthopedic Disorders
  • Mr. Michael Schuster MS, BSc, MBA, Head of Pharma Partnering (Age 42)
  • Dr. Kenneth M. Borow M.D., Exec. (Age 71)

When did Mesoblast IPO?

(MESO) raised $69 million in an initial public offering on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

What is Mesoblast's stock symbol?

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

How do I buy shares of Mesoblast?

Shares of MESO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mesoblast's stock price today?

One share of MESO stock can currently be purchased for approximately $18.58.

How big of a company is Mesoblast?

Mesoblast has a market capitalization of $2.18 billion and generates $32.16 million in revenue each year. The company earns $-77,940,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. Mesoblast employs 81 workers across the globe.

What is Mesoblast's official website?

The official website for Mesoblast is www.mesoblast.com.

How can I contact Mesoblast?

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at 61-3-9639-6036 or via email at [email protected]

This page was last updated on 10/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.